Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer

Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer

British Journal of Cancer 117, 974 (26 September 2017). doi:10.1038/bjc.2017.292

Authors: Meng Li, Jingyu Yang, Wenlong Zhou, Yong Ren, Xiaoxuan Wang, Huiping Chen, Jingyuan Zhang, Junli Chen, Yuhong Sun, Lijuan Cui, Xing Liu, Lihui Wang & Chunfu Wu

http://ift.tt/2gpfBv7